CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Natural killer (NK) cells comprise a unique population of innate lymphoid cells endowed with
intrinsic abilities to identify and eliminate virally infected cells and tumour cells. Possessing …

Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Metabolic reprogramming toward glycolysis is a hallmark of cancer malignancy. The
molecular mechanisms by which the tumor glycolysis pathway promotes immune evasion …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

One hundred years have passed since Warburg discovered alterations in cancer
metabolism, more than 70 years since Sidney Farber introduced anti-folates that …

Immune checkpoint therapy via PD-1 antibodies has shown exciting clinical value and
robust therapeutic potential in clinical practice. It can significantly improve progression-free …

How glucose metabolism remodels pro-tumor functions of tumor-associated macrophages
(TAMs) needs further investigation. Here we show that M2-like TAMs bear the highest …

Accumulating evidence suggests that metabolic rewiring in malignant cells supports tumour
progression not only by providing cancer cells with increased proliferative potential and an …

The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …